Back to Search
Start Over
InterMune Canada Inc release: game changing therapy for idiopathic pulmonary fibrosis now available in Canada
- Source :
- Chemical Business Newsbase. January 17, 2013
- Publication Year :
- 2013
-
Abstract
- Following Health Canada's market approval of Esbriet (pirfenidone) on 1 Oct 2012, InterMune Canada Inc has announced that the only treatment indicated for mild to moderate idiopathic pulmonary fibrosis (IPF) [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Chemical Business Newsbase
- Publication Type :
- News
- Accession number :
- edsgcl.316299632